HER1-3 and Death Receptor protein folding as therapeutic vulnerabilities
HER1-3 和死亡受体蛋白折叠作为治疗漏洞
基本信息
- 批准号:10721930
- 负责人:
- 金额:$ 20.96万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-07-07 至 2025-06-30
- 项目状态:未结题
- 来源:
- 关键词:AGR2 geneActive SitesAdvanced Malignant NeoplasmAdverse effectsAffectAfrican AmericanAgonistAmericanAnimal ModelAnimalsAntineoplastic AgentsApoptosisApoptoticAutopsyBindingBiological MarkersBlood Cell CountBreastBreast Cancer CellBreast Cancer PatientCASP8 geneCell DeathCell surfaceCessation of lifeChemicalsClientClinicalClinical TrialsDependenceDisseminated Malignant NeoplasmDisulfidesDoseDown-RegulationDrug KineticsDrug resistanceERBB2 geneERBB3 geneEpidermal Growth Factor ReceptorEthnic PopulationExhibitsFamilyFormulationFutureHealthHeterodimerizationHistologicHumanIGF1R geneInduction of ApoptosisKidneyKnock-outLigandsLinkLiverMalignant NeoplasmsMediatingMedicineMetabolismModelingMonitorMusMuscleNeedle biopsy procedureNeoplasm MetastasisNormal CellNormal tissue morphologyOncogenicOncoproteinsPathway interactionsPatientsPharmaceutical PreparationsPlasmaPreparationPrimary NeoplasmPropertyProtein Disulfide IsomeraseProtein InhibitionProteinsPublishingReceptor Protein-Tyrosine KinasesRefractoryResistanceRoleRouteSafetySamplingSignal TransductionStructureTNFRSF10A geneTNFRSF10B geneTherapeuticToxic effectTumor EscapeTumor Necrosis Factor ReceptorTumor Necrosis FactorsUp-RegulationWomanWorkadvanced breast canceranti-cancerbiomarker validationbreast cancer survivalcancer cellcancer subtypescancer survivalcarcinogenesisclinically relevantdisulfide bonddosageimprovedin vivoinhibitormalignant breast neoplasmmortalityoverexpressionpatient stratificationpharmacokinetics and pharmacodynamicspharmacologicpreclinical efficacypreclinical studypredictive markerpreventprotein foldingreceptorrefractory cancerresponsetargeted agenttherapeutically effectivetherapy resistanttreatment effecttriple-negative invasive breast carcinomatumor
项目摘要
Breast cancer remains a major killer of women due to the ineffectiveness of current drugs against
metastatic and drug-resistant cancers. Additionally, African American (AA) women suffer
disproportionately from breast cancer mortality in part because they develop the aggressive Triple-
Negative Breast Cancer (TNBC) subtype more frequently than other ethnic groups. Thus, agents
effective against drug-resistant and metastatic cancers and TNBCs may improve the survival of
breast cancer patients. These aggressive cancers evade cell death through a variety of mechanisms
including overactivation of the pro-survival HER-family of Receptor Tyrosine Kinases (RTKs),
including EGFR/HER1, HER2, and HER3 (HER1-3), and inactivation of pro-apoptotic signaling.
Tumors expressing HER1-3 are difficult to treat due to the partial redundancy among these receptors,
their oncogenic signaling as heterodimers, and their ability to aberrantly heterodimerize with non-HER
RTKs such as MET and IGF1R. Thus, resistance to current HER-targeted agents is a significant
clinical problem. Defective cancer cell apoptosis can result from inactivation of the TNF Receptor
Apoptosis Inducing Ligand (TRAIL)/Death Receptor 4/5 (DR4/5) pathway, which selectively kills
cancer cells, while not affecting normal cells. Tumor resistance to TRAIL and other DR4/5 agonists
results primarily from poor pharmacological properties of the agonists and the ability of cancer cells to
downregulate DR4/5. Consequently, agents that could inactivate the EGFR/HER2/HER3 signaling
axis and upregulate and activate DR4/5 independently of the TRAIL ligand may be efficacious against
breast cancers unresponsive to current medicines. Disulfide bond Disrupting Agents (DDAs) are a
new class of anti-cancer agents that induce regression of primary tumors and metastatic lesions of
drug-resistant patient-derived tumors in animal models. In addition to the structural uniqueness of
DDAs, recent studies indicate that DDAs are the first identified active site inhibitors of the Protein
Disulfide Isomerases (PDIs) ERp44 and AGR2. Further, DDA inhibition of the PDIs ERp44, AGR2,
and PDIA1 alters the disulfide bonding of HER1-3 and DR4/5, resulting in HER1-3 downregulation,
DR5 upregulation, and disulfide bond-mediated oligomerization and activation of DR4/5. The
objective of the current project is to move DDAs toward clinical trials. The two Specific Aims proposed
to achieve this objective are to 1) optimize DDA pharmacological properties and dosing for future
IND-enabling studies, and 2) validate biomarkers to predict tumor sensitivity to DDAs and to monitor
target engagement, and thoroughly evaluate any adverse effects of DDAs on normal tissues or
animal health. Based on their unique mechanisms of action and preclinical efficacy, we expect DDAs
to benefit breast cancer patients with treatment-refractory breast cancers.
乳腺癌仍然是妇女的主要杀手,由于目前的药物无效,
转移性和耐药性癌症。此外,非洲裔美国人(AA)妇女遭受
不成比例的乳腺癌死亡率,部分原因是他们发展了积极的三重-
阴性乳腺癌(TNBC)亚型比其他种族更常见。因此,代理
有效对抗耐药性和转移性癌症和TNBC可能会改善患者的生存期。
乳腺癌患者。这些侵袭性癌症通过多种机制逃避细胞死亡
包括受体酪氨酸激酶(RTK)的促存活HER家族的过度活化,
包括EGFR/HER 1、HER 2和HER 3(HER 1 -3),以及促凋亡信号传导的失活。
表达HER 1 -3的肿瘤由于这些受体之间的部分冗余而难以治疗,
它们作为异二聚体的致癌信号传导,以及它们与非HER异常异二聚化的能力,
RTK,如MET和IGF 1 R。因此,对当前HER靶向剂的抗性是一个显著的不利因素。
临床问题肿瘤坏死因子受体失活可导致癌细胞凋亡缺陷
凋亡诱导配体(TRAIL)/死亡受体4/5(DR 4/5)途径,选择性杀死
癌细胞,而不影响正常细胞。肿瘤对TRAIL和其他DR 4/5激动剂的耐药性
主要是由于激动剂的药理学性质较差以及癌细胞的能力造成的
下调DR 4/5。因此,可以抑制EGFR/HER 2/HER 3信号传导的药物
轴和上调和激活DR 4/5独立的TRAIL配体可能是有效的,
乳腺癌对现有药物无反应。二硫键破坏剂(DDAs)
诱导原发性肿瘤和转移性病灶消退的一类新的抗癌剂,
在动物模型中的耐药患者来源的肿瘤。除了结构上的独特性,
DDAs,最近的研究表明,DDAs是第一个确定的蛋白质活性位点抑制剂
二硫化物异构酶(PDI)ERp 44和AGR 2。此外,DDA抑制PDIs ERp 44,AGR 2,
PDIA 1改变HER 1 -3和DR 4/5的二硫键,导致HER 1 -3下调,
DR 5上调和二硫键介导的DR 4/5寡聚化和活化。的
当前项目的目标是将DDA推向临床试验。提出的两个具体目标
为了实现这一目标,1)优化DDA的药理学性质和未来的剂量,
IND使能研究,和2)验证生物标志物,以预测肿瘤对DDA的敏感性,并监测
靶向接合,并彻底评估DDA对正常组织的任何不良影响,
动物健康基于其独特的作用机制和临床前疗效,我们预计
以使患有难治性乳腺癌的乳腺癌患者受益。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Brian K. Law其他文献
Frameless Stereotactic Navigation in Transsphenoidal Surgery: Comparison with Fluoroscopy
经蝶手术中的无框架立体定向导航:与透视检查的比较
- DOI:
10.1159/000076660 - 发表时间:
2004 - 期刊:
- 影响因子:1.7
- 作者:
I. McCutcheon;Ryan S. Kitagawa;Paula F. Demasi;Brian K. Law;K. Friend - 通讯作者:
K. Friend
Brian K. Law的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Brian K. Law', 18)}}的其他基金
Regulation of Death Receptor 5 folding and apoptotic signaling by AGR2
AGR2 对死亡受体 5 折叠和细胞凋亡信号的调节
- 批准号:
10042651 - 财政年份:2020
- 资助金额:
$ 20.96万 - 项目类别:
Rapamycin Potentiates TGFb Tumor Suppressor Function
雷帕霉素增强 TGFb 肿瘤抑制功能
- 批准号:
7225278 - 财政年份:2003
- 资助金额:
$ 20.96万 - 项目类别:
Rapamycin Potentiates TGFb Tumor Suppressor Function
雷帕霉素增强 TGFb 肿瘤抑制功能
- 批准号:
7090095 - 财政年份:2003
- 资助金额:
$ 20.96万 - 项目类别:
Rapamycin Potentiates TGFb Tumor Suppressor Function
雷帕霉素增强 TGFb 肿瘤抑制功能
- 批准号:
6678797 - 财政年份:2003
- 资助金额:
$ 20.96万 - 项目类别:
Rapamycin Potentiates TGFb Tumor Suppressor Function
雷帕霉素增强 TGFb 肿瘤抑制功能
- 批准号:
6947331 - 财政年份:2003
- 资助金额:
$ 20.96万 - 项目类别:
Rapamycin Potentiates TGFb Tumor Suppressor Function
雷帕霉素增强 TGFb 肿瘤抑制功能
- 批准号:
6773355 - 财政年份:2003
- 资助金额:
$ 20.96万 - 项目类别:
相似海外基金
Collaborative Research: Beyond the Single-Atom Paradigm: A Priori Design of Dual-Atom Alloy Active Sites for Efficient and Selective Chemical Conversions
合作研究:超越单原子范式:双原子合金活性位点的先验设计,用于高效和选择性化学转化
- 批准号:
2334970 - 财政年份:2024
- 资助金额:
$ 20.96万 - 项目类别:
Standard Grant
NSF-BSF: Towards a Molecular Understanding of Dynamic Active Sites in Advanced Alkaline Water Oxidation Catalysts
NSF-BSF:高级碱性水氧化催化剂动态活性位点的分子理解
- 批准号:
2400195 - 财政年份:2024
- 资助金额:
$ 20.96万 - 项目类别:
Standard Grant
Collaborative Research: Beyond the Single-Atom Paradigm: A Priori Design of Dual-Atom Alloy Active Sites for Efficient and Selective Chemical Conversions
合作研究:超越单原子范式:双原子合金活性位点的先验设计,用于高效和选择性化学转化
- 批准号:
2334969 - 财政年份:2024
- 资助金额:
$ 20.96万 - 项目类别:
Standard Grant
Mechanochemical synthesis of nanocarbon and design of active sites for oxygen reducton/evolution reactions
纳米碳的机械化学合成和氧还原/演化反应活性位点的设计
- 批准号:
23K04919 - 财政年份:2023
- 资助金额:
$ 20.96万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Creation of porous inorganic frameworks with controlled structure of metal active sites by the building block method.
通过积木法创建具有金属活性位点受控结构的多孔无机框架。
- 批准号:
22KJ2957 - 财政年份:2023
- 资助金额:
$ 20.96万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Catalysis of Juxaposed Active Sites Created in Nanospaces and Their Applications
纳米空间中并置活性位点的催化及其应用
- 批准号:
23K04494 - 财政年份:2023
- 资助金额:
$ 20.96万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Generation of carbon active sites by modifying the oxygen containing functional groups and structures of carbons for utilizing to various catalytic reactions.
通过修饰碳的含氧官能团和结构来产生碳活性位点,用于各种催化反应。
- 批准号:
23K13831 - 财政年份:2023
- 资助金额:
$ 20.96万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
CAREER: CAS: Understanding the Chemistry of Palladium and Silyl Compounds to Design Catalyst Active Sites
职业:CAS:了解钯和甲硅烷基化合物的化学性质以设计催化剂活性位点
- 批准号:
2238379 - 财政年份:2023
- 资助金额:
$ 20.96万 - 项目类别:
Continuing Grant
CAS: Collaborative Research: Tailoring the Distribution of Transient vs. Dynamic Active Sites in Solid-Acid Catalysts and Their Impacts on Chemical Conversions
CAS:合作研究:定制固体酸催化剂中瞬时活性位点与动态活性位点的分布及其对化学转化的影响
- 批准号:
2154399 - 财政年份:2022
- 资助金额:
$ 20.96万 - 项目类别:
Standard Grant
Engineering of Active Sites in Heterogeneous Catalysts for Sustainable Chemical and Fuel Production.
用于可持续化学和燃料生产的多相催化剂活性位点工程。
- 批准号:
RGPIN-2019-06633 - 财政年份:2022
- 资助金额:
$ 20.96万 - 项目类别:
Discovery Grants Program - Individual